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Edited by Laszlo NagyAbstract We analysed the eﬀects of high cholesterol (HC)
intake and reduced apolipoprotein E (apoE) activity on tau phos-
phorylation and on the activities of the major tau kinases and
phosphatases in brains from wild-type and apoE-knockout (apo-
EKO) mice. We show that HC diet potently induced intraneuro-
nal accumulation of hyperphosphorylated tau in apoEKO mice,
as well as upregulation of several tau kinases, without aﬀecting
tau phosphatases. Our results suggest an interaction between die-
tary and genetic factors in the development of tauopathies, which
can be relevant in humans, where the apoE4 isoform could have a
lack of function as compared to other isoforms.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Abnormal phosphorylation of the tau protein leading to the
formation of neuroﬁbrillary tangles (NFTs) is a common fea-
ture of Alzheimers disease (AD), frontotemporal dementia
(FTD), and a growing list of other neurodegenerative disorders
[1]. It is believed that tau hyperphosphorylation compromises
the normal functioning of the neuron leading to its death.
The state of tau phosphorylation is thought to result from the
balance between activities of several kinases and phosphatases,
including the kinases glycogen synthase kinase-3 (GSK-3),
cyclin-dependent protein kinase-5 (cdk-5), extracellular regula-
tory kinase (ERK) 1/2, calmodulin-dependent protein kinase II
(CaMKII), protein kinase A (PKA), the stress-activated c-JunAbbreviations: AD, Alzheimers disease; apoE, apolipoprotein E;
apoEKO, apoE-knockout; CaMKII, calmodulin-dependent protein
kinase II; cdk-5, cyclin-dependent protein kinase-5; ERK, extracellular
regulatory kinase; FTD, frontotemporal dementia; GSK-3, glycogen
synthase kinase-3; HC, high cholesterol; NFTs, neuroﬁbrillary tangles;
NPC, Niemann-Pick type C disease; ND, normal diet; PBS, phos-
phate-buﬀered saline; PKA, protein kinase A; PP, protein phospha-
tase; WT, wild-type
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doi:10.1016/j.febslet.2005.10.024N-terminal kinase (JNK) and p38 kinase, and the phosphatases
PP2A, PP2B and PP1 [2]. However, to date the molecular
mechanisms causing tau hyperphosphorylation in neurons are
not fully understood.
Abnormal tau hyperphosphorylation is distinctive of the
pathogenesis of Niemann-Pick type C disease (NPC), a heredi-
tary neurodegenerative disorder characterised byadefect in cho-
lesterol metabolism [3]. Increasing evidence indicates that
cholesterol also plays a role in ADneuropathogenesis. Epidemi-
ological studies has shown a relation between high serum
cholesterol levels and AD [4–6] and between the use of choles-
terol-lowering drugs and a decreased risk for dementia [7]. In
addition, amajor risk factor forAD is the presence of the E4 iso-
form of apolipoprotein E (apoE), a protein considered to be the
major cholesterol transporter in the brain [8]. ApoE4 has also
been linked to several other neurodegenerative disorders,
including diﬀerent tauopathies [9], and has been associated with
tau hyperphosphorylation in several animal models [10,11].
Interestingly, high fat and cholesterol intake may be risk factors
for AD among individuals carrying the apoE4 isoform [12]. To-
gether these ﬁndings suggest that defects in cholesterol metabo-
lism could play a role in the abnormal phosphorylation of tau
and that interactions between dietary cholesterol and apoE
may determine the risk for neurodegenerative disorders.
Several studies on apoE-knockout (apoEKO) mice have
conﬁrmed an association between reduced apoE activity and
neuronal alterations, including increased oxidative stress and
neurodegeneration [13–15], as well as activation of glial cells
[16,17]. There are conﬂicting data regarding tau phosphoryla-
tion in apoEKO mice, i.e., being either elevated or unchanged
[18,19].
To further analyse the interactions between high cholesterol
(HC) intake and reduced apoE activity that might lead to neu-
rodegenerative disorders, we have examined the phosphoryla-
tion of tau and the activities of major tau kinases and
phosphatases in brains from wild-type (WT) and apoEKO
mice on normal diet (ND) and HC diet.2. Materials and methods
2.1. Animals
Five-to-six weeks old apoEKO mice and the WT background strain
C57BL/6 were purchased from Mo¨llega˚rd Laboratory, Denmark, and
B&K Sweden, respectively. The animals were housed in groups of ﬁveblished by Elsevier B.V. All rights reserved.
Table 1
List of primary antibodies
Antibody Speciﬁcity Company
AT-8 Tau p-tau (S202/T205) 1
AT-100 Tau p-tau (T212/S214) 1
AT-180 Tau p-tau (T231) 1
Tau Total tau 2
CamkII Total CamkII 3
p-CamkII p-CamkII (Thr 286) 4
Cdk5 Total Cdk5 5
Cdk5-p35 Neuron activator of cdk5 5
ERK Total ERK 6
p-ERK (1/2) p-ERK 1/2 (T202/Y204) 4
GSK-3b Total GSK-3b 6
p-GSK-3b (S9) p-GSK-3b (S9) 3
p-GSK-3 (Y216) p-GSK-3a (Y279);
p-GSK-3b (Y216)
3
JNK Total JNK 4
p-JNK p-JNK(T183/Y185) 4
p38 Total p38 4
p-p38 p-p38 (T180/Y182) 4
Akt Total Akt 4
p-Akt p-Akt (S473) 4
(1) Innogenetics (Gent, Belgium); (2) Dakocytomation (Denmark);
(3) Biosource (Nivelles, Belgium); (4) Cell Signalling Technology
(Beverly, MA, USA); (5) Santa Cruz Biotechnology (Santa Cruz, CA,
USA); (6) BD Transduction Laboratories (Lexington, KY, USA).
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tamine, Sweden) for 9 months. Ethical consent was received from the
regional ethical committee for animal studies (S31-02).
2.2. Tissue preparation
For immunohistochemistry, four animals per group (two males and
two females) were anaesthetised intraperitoneally (i.p.) with sodium
chloral hydrate (40 mg/100 g) and perfused transcardially with 20 ml
of 0.1 M phosphate-buﬀered saline (PBS) followed by 60 ml 4% para-
formaldehyde in 0.1 M PBS, pH 7.4, for 10 min. Animals were decap-
itated and the brains were removed, post-ﬁxed in the same ﬁxative for
8 h, and then soaked in 10% sucrose in 0.1 M So¨rensen phosphate
buﬀer, pH 7.4, for at least 24 h. The brains were cut on a cryostat
and 14 lm thick coronal sections were collected at four levels (0.74,
0.02, 1.82 and 2.80 mm) in relation to bregma, according to the
Franklin & Paxinos atlas [20]. The sections were kept at 20 C until
processing.
For immunoblotting and for assays of PKA, PP2A, PP2B and PP1
activities, eight animals per group (four males and four females) were
sacriﬁced by decapitation and the brains immediately frozen and
stored at 70 C. One hemisphere of each brain was homogenised in
a buﬀer containing 40 mM Tris–HCl (pH 6.8), 1% NP-40, a protease
inhibitor cocktail (Sigma–Aldrich, St. Louis, MO, USA; 1:500) and
phosphatase inhibitors (20 mM b-glycerophosphate, 2 nM okadaic
acid, 50 mM NaF, 1 mM Na3VO4) for immunoblotting. The other
hemisphere was homogenised in modiﬁed RIPA buﬀer (50 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40) with protease
inhibitor cocktail (Sigma–Aldrich; 1:500), to be used for assays of
phosphatases and PKA activities.
2.3. Immunohistochemistry
Immunohistochemistry was performed as described previously [17]
using AT-8 as primary antibody (1:1000, over night at 4–8 C) for
detection of phosphorylated tau (p-tau). The sections were then rinsed
in PBS and incubated with biotinylated horse anti-mouse IgG for 1 h
at room temperature (RT). With rinses in PBS between steps, the sec-
tions were incubated with avidin-biotin-peroxidase complex (Vecta-
stainElite, Vector Laboratories) (30 min at RT), exposed to
diaminobenzidine and mounted with mounting medium (Dako Cyto-
mation, Denmark). Omission of the primary antibody was used as a
negative control.
2.4. Western blotting
Equal amounts of protein were separated using 10% acrylamide gels.
The proteins were transferred to a nitrocellulose membrane (Schleicher
& Schuell, Germany). Incubations with primary antibodies (see Table
1) were performed over night at 1:1000 dilution. After rinsing, horse-
radish peroxidase-linked, anti-rabbit or anti-mouse IgG (Amersham
Biosciences, Little Chalfont, England, 1:2000) was applied for 1 h.
Immunoreactivity was detected by the ECL detection system (Amer-
sham Biosciences). Some immunoblots were stripped using stripping
buﬀer (62.5 mM Tris–HCl, pH 6.7, 2% SDS, 100 mM mercap-
toethanol) at +50 C for 30 min, and then re-blotted with other anti-
bodies. The relative density of the immunoreactive bands was
calculated from the optical density multiplied by the area of the se-
lected band using NIH Image 1.62 software.
2.5. PKA activity assay
PKA activity was assayed using a SpinszymeTM colorimetric kit
from Pierce (Rockford, IL, USA) according to the manufacturers
instructions. 40 ll of brain homogenate containing 30.0 lg of protein
were analysed.
2.6. PP1, PP2A and PP2B activity assays
Activities of the protein phosphatases (PPs) PP1, PP2A and PP2B
were measured using a RediPlate 96 EnzChek Serine/Threonine Phos-
phatase Assay kit from Invitrogen AB (Ta¨by, Sweden) according to
the manufacturers protocol. This kit uses a speciﬁc buﬀer for each
phosphatase and a phosphate substrate (DiFMUP) that generates
the ﬂuorescent product DiFMU, when cleaved. The ﬂuorescence was
measured by a CytoFluor 4000 (PerSeptive Biosystems), the excitation
and emission wavelengths being 345 and 490 nm, respectively. From
each brain a sample of 32.25 lg of homogenate was used.2.7. Statistical analyses
Statistical analysis was carried out by analysis of variance
(ANOVA) followed by Fishers protected least signiﬁcant diﬀerence
(PLSD) post hoc test. A value of P < 0.05 was considered statistically
signiﬁcant.3. Results
3.1. Increase in tau phosphorylation in apoEKO mice after HC
diet
Immunohistochemical analysis of brain sections with the
monoclonal antibody AT-8 revealed the presence of abundant
intraneuronal inclusions of P-tau in apoEKO mice on HC
diet (Figs. 1 and 2). P-tau immunoreactivity was particularly
strong in neurons in the cerebral cortex, especially in the ret-
rosplenial cortex (Fig. 1D and H) and in lateral parts of the
cortex (not shown). Intense labelling was also seen in the den-
tate gyrus of the hippocampus in some of the apoEKO ani-
mals on HC diet (Fig. 2D), particularly in the polymorphic
layer. A smaller number of weakly labelled neurons was seen
in other animals of this group (apoEKO mice on HC diet;
data not shown). ApoEKO mice on ND and WT animals
on ND or HC diet only showed occasional neuronal staining
(not shown).
P-tau immunoreactivity could be seen in cells with microg-
lia-like morphology in both WT mice and apoEKO mice (Figs.
1 and 2) regardless of diet.
Western blot analysis of the cerebral cortex using the mono-
clonal antibodies AT-8, AT-100 and AT-180 (Fig. 3) revealed
that HC diet markedly increased P-tau immunoreactivity in all
apoEKO animals. An increase in P-tau immunoreactivity was
also seen in two female apoEKO mice on ND and in one fe-
male WT mouse on HC diet (Fig. 3). Re-blotting of the mem-
branes with the phosphorylation-independent Tau antibody
revealed no diﬀerences in total tau levels between the experi-
mental groups (Fig. 3).
Fig. 1. Micrographs of sections of the cerebral cortex from WT (A, B, E, F) and apoEKO (C, D, G, H) mice with ND (A, C, E, G) and HC diet (B,
D, F, H). The sections were stained with AT-8, a monoclonal antibody that recognises phosphorylated tau (P-tau). In apoEKO mice on HC diet (D,
H), intense AT-8 immunoreactivity can be seen in the cytoplasm of neurons. A weak P-tau immunoreactivity is seen in cells with microglia-like
morphology in all animal groups (arrows). Asterisks in A–D indicate the corpus callosum. Bars indicate 50 lm in A–D and 10 lm in E–H.
Fig. 2. Micrographs of sections of the hippocampal dentate gyrus from WT (A, B) and apoEKO (C, D) mice with ND (A, C) and HC diet (B, D).
The sections were stained with AT-8, a monoclonal antibody that recognises phosphorylated tau (P-tau). Intense P-tau immunoreactivity can be seen
in neuronal cell bodies in the dentate gyrus of the apoEKO mice on HC diet (D). Cells with microglia-like morphology with P-tau immunoreactivity
can be seen in all animal groups (arrows in A). All micrographs are of the same magniﬁcation. Bars indicate 10 lm.
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phosphatases in WT and apoEKO mice brains
We next investigated the activities of various protein kinases
and phosphatases implicated in the regulation of tau phos-
phorylation in the cerebral cortex of WT and apoEKO mice
after ND or HC diet. Akt, CamKII, Cdk5, ERK 1/2, GSK-
3, JNK, and p38 kinases are known to phosphorylate tau at
sites that are recognised by the AT8, AT100 and AT180 P-
tau antibodies (see Table 2). These kinases were analysed by
Western blotting (see Fig. 4), using commercially available
antibodies. As indication of the activity, the ratio of the immu-
noreactivity of the active phosphorylated form and the total
level of each kinase was calculated. In the case of GSK-3b,
both the active (phosphorylated at Tyr-216) and the inactive(phosphorylated at Ser-9) forms were investigated (Fig. 4).
The activity of PKA was measured by a speciﬁc activity assay
as described in Section 2. For a better understanding, the ob-
tained data were expressed as percentage of the values seen in
WT animals on ND, for the respective kinase. The results are
summarised in Fig. 4 and Table 3.
In WT mice there was no signiﬁcant change upon HC diet
in the activity of any of the kinases investigated. The activi-
ties of CamKII and PKA were signiﬁcantly higher in apo-
EKO, than in WT mice (Fig. 4 and Table 3), independently
of the diet. The HC diet resulted in a further increase as com-
pared to the ND in the apoEKO animals. ApoEKO mice on
HC diet showed signiﬁcantly higher activities of cdk-5, GSK-
3b (with enhanced Tyr-216 phosphorylation and unchanged
Fig. 3. Immunoblots of cerebral cortex homogenates from WT and
apoEKOmice with ND and HC diet using the anti-phosphorylated tau
antibodies AT-8, AT-100 and AT-180 and the phosphorylation-
independent antibody Tau. Four individuals are presented from each
group.
6414 A. Rahman et al. / FEBS Letters 579 (2005) 6411–6416Ser-9 phosphorylation), JNK and p38 kinases, than apoEKO
mice on ND, and compared to WT mice. No signiﬁcant
changes between groups were found in the activities of AktTable 2
Tau-directed protein kinase sites [35–37]
AKT T212
CamkII S262, S285, S356, S403, S416
Cdk5 T153, S195, S202, T205, T212
ERK1/2 S46, T50, T69, T153, T175, T
GSK-3b S46, T50, T69, T153, T175, T
S202, T205, S208, T212, S214
JNK T153, T175, T181, S202, T205
P38 S46, T50, T153, T175, T181, S
PKA S195, S198, S202, T205, T212
The anti-P-tau antibody AT8 recognises the sites underlined, AT100 the bold
Fig. 4. Immunoblots of cerebral cortex homogenates from WT and apoE
phosphorylated forms of Akt, CamKII, Cdk5, ERK 1/2, GSK-3, JNK, and
group.and ERK 1/2. Also, there were no signiﬁcant changes in
the total levels of the proteins analysed among the groups
of our study.
No signiﬁcant diﬀerences were found in the cortical levels of
PP1, PP2A and PP2B activities between WT and apoEKO
mice, nor between mice with ND and HC diet (see Table 3).4. Discussion
Abnormal hyperphosphorylation of tau leading to the for-
mation of NFTs is a common feature of several neurodegener-
ative disorders. Deﬁciency in cholesterol metabolism is the
direct cause of some of these tauopathies such as in NPC,
and increasing evidence suggests that it contributes to the
pathology of other disorders including AD. Moreover, the
presence of the E4 isoform of apoE, the main cholesterol trans-
porter in the brain, confers higher risk for several tauopathies, S214, T231, S235, S396, S404
181, S199, S202, T212, S396, S404
181, S184, S195, S198, S199,
, T217, T231, S235, S262, S396, S400, T403, S404
, T212, T217, T231, S235, S356, S396
199, S202, T205, T212, T217, S235, T246, S356, S396, S404, S422
, S214, S237, S262, S293, S305, S320, S324, S356, S403, S416
sites and AT180 the underlined bold sites.
KO mice on ND and HC diet using antibodies against the active
p38 kinases (see Table 1). Four individuals are presented from each
Table 3
Activities of tau kinases and phosphatases in cerebral cortex homogenates from WT and apoEKO mice on ND and HC diet
Kinases WT-ND WT-HC KO-ND KO-HC
Akt 100 ± 3.2 104 ± 12.8 94.3 ± 6.7 92.4 ± 11.5
CamkII 100 ± 3.3 140.7 ± 27.1 151.1 ± 11.7* 251.2 ± 49.3***,#
Cdk5 100 ± 6.7 125.1 ± 5.9 106.2 ± 11.7 173.7 ± 27.9*,#
ERK p42 100 ± 13.0 131.3 ± 19.8 85.5 ± 11.7 92.0 ± 8.3
ERK p44 100 ± 7.4 140.1 ± 22.0 99.7 ± 10.8 118.2 ± 13.6
GSK-3a 100 ± 8.5 117.0 ± 10.3 112.5 ± 15.5 173.3 ± 32.0**,#
GSK-3b 100 ± 9.1 124.0 ± 13.2 104.6 ± 12.8 160.3 ± 20.7**,#
JNK p46 100 ± 7.3 100.7 ± 22.0 94.2 ± 7.7 149 ± 11.4**,##
p38 100 ± 4.2 97.5 ± 18.7 114.1 ± 15.2 161.9 ± 25.9*,#
PKA 100 ± 2.6 108.0 ± 2.7 111.2 ± 3.0* 139.4 ± 5.2**,#
Phosphatases
PP1 100 ± 15.2 154.0 ± 45.1 132.8 ± 20.0 158.6 ± 38.2
PP2A 100 ± 15.0 87.6 ± 16.7 108.1 ± 9.3 108.1 ± 13.2
PP2B 100 ± 5.3 137.1 ± 33.1 138.2 ± 16.4 116.8 ± 12.0
Data are means ± S.E.M. of eight animals per group with values expressed as percentage of those seen in WT animals on ND. *P < 0.05, **P < 0.01,
and ***P < 0.001 against WT on ND. #P < 0.05 and ##P < 0.01 against KO on ND.
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the lack of function provided by apoE4, as compared to
apoE3, in binding and protecting tau from hyperphosphoryla-
tion, could be the reason for these associations [22]. In addi-
tion, dietary factors such as HC intake may interact with the
apoE genotype in exacerbating the risk for neurodegenerative
disorders [23].
We have addressed these issues by studying the state of tau
phosphorylation in WT and apoEKO mice on ND or HC diet.
The apoE deﬁciency in apoEKO mice is considered an equiv-
alent of the loss of function resulting from the presence of the
apoE4 allele in humans. We show that HC diet potently and
invariably induced tau hyperphosphorylation in the brain of
apoEKO mice. The accumulated P-tau was phosphorylated
at epitopes seen to be phosphorylated in several tauopathies
including AD, NPC and FTD [2]. The intraneuronal P-tau
inclusions were abundant in the cerebral cortex and in the den-
tate gyrus, but less apparent in other parts of the hippocam-
pus. This region-speciﬁc accumulation of P-tau inclusions
would seem to resemble the pathology in FTD, rather than
in AD [24].
There are conﬂicting results in the literature regarding the ef-
fects of apoE deﬁciency on tau phosphorylation. Previous re-
ports from Genis et al. [19,25] showed increased P-tau levels
in whole brain homogenates from apoEKO mice on ND.
However, this was not seen by others [18,26]. Bi et al. [27] re-
ported the presence of AT-8 immunolabelled cells in some, but
not all, apoEKO mice analysed. In our study on a total num-
ber of 12 animals per group, only two female apoEKO mice on
ND, as well as one WT mouse on HC diet, showed increased
tau phosphorylation. The explanation for these contrasting re-
sults using apoKO mice with the same background strain and
similar biochemical techniques remains to be explained. In
view of our observations, it is tempting to speculate that fe-
males may be more susceptible to neuronal accumulation of
P-tau upon HC diet or upon deﬁciency of apoE. Nevertheless,
it is conceivable that apoE deﬁciency may increase neuronal
vulnerability to hyperphosphorylation of tau, without being
the direct cause of it.
To explore the mechanism by which tau is hyperphospho-
rylated in apoEKO animals on HC diet, we investigated the
activities of the major kinases and phosphatases responsible
for the phosphorylation state of tau. ApoEKO mice onHC diet had signiﬁcantly increased activities of cdk-5,
GSK-3, JNK and p38 kinases. The CamKII and PKA activ-
ities were increased in apoEKO mice regardless of the diet,
although the enhancement was greater in those on HC diet.
No signiﬁcant eﬀects of the HC diet were observed in WT
animals.
The speciﬁc role of each of these kinases in the abnormal
hyperphosphorylation of tau remains unknown. Several
immunohistochemical studies have shown increased expression
of several active kinases co-localising with NFTs in AD brains
[2]. Also, increased activity of PKA or CamKII has been
shown to enhance the phosphorylation of tau by other kinases
such us GSK-3 and cdk-5 [28,29]. Our data suggest that upreg-
ulation of cdk-5, GSK-3, JNK and p38 activities would partic-
ipate in the abnormal phosphorylation of tau seen in apoEKO
mice on HC diet. Increased PKA and CamKII activities could
also contribute to this eﬀect and to the enhanced tau phos-
phorylation seen in some apoEKO mice on ND.
A clear relationship has been described between tau phos-
phorylation and oxidative stress [30,31], possibly by the upreg-
ulation of several tau kinases [32–34]. A similar mechanism
could be suggested here in view of our recent ﬁndings that
HC diet induces enhanced expression of an antioxidant en-
zyme in the brain of apoEKO mice [17]. However, the reasons
by which cortical neurons are more vulnerable to undergo
tau hyperphosphorylation in these animals remain to be
elucidated.
The activities of PP2A and PP1 have been shown to be de-
creased in AD brains, and it is suggested that this could con-
tribute to the abnormal phosphorylation of tau seen in this
disease [2]. We found that apoE deﬁciency, HC diet or a com-
bination of both, did not produce signiﬁcant diﬀerences in
either PP1, PP2A or PP2B activities, suggesting that the in-
creased tau phosphorylation seen in apoEKO mice on HC diet
is not due to a deﬁcit in tau dephosphorylation.
In summary, we have demonstrated that the combination of
apoE deﬁciency and long-term HC intake results in the intran-
euronal accumulation of hyperphosphorylated tau, probably
by increasing the activity of several tau kinases. This interac-
tion between dietary and genetic factors could be relevant
for the development of tauopathies in humans, where the
apoE4 isoform may have a lack of function as compared to
other isoforms.
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